Are These Cheap Stocks On Your Coronavirus Watch List This Week?
Whether you’re looking for penny stocks under 10 cents or ones that are a bit higher in price, the same goals are in place. The whole point of trading is to make money and when it comes to penny stocks, those gains can come quickly.
Obviously, simple math suggests that the lower the price, the smaller the price move needs to be in order to see larger returns. Herein lies the risk/reward scenario. Just as small a price move creates big gains it can also equate to hefty losses.
Let’s say you’ve got a few penny stocks in front of you. Some are stocks under $5 – maybe trading around $4, for example. Others are these lower-priced penny stocks under 10 cents. If your $4 stock moves up or down by 4 cents, the percentage change is 1%; nominal. However, if your penny stocks under 10 cents experience a move of 4 cents, you’re talking about 40% or more. Now, a lot of this depends on the shares structure as well.
I’ve seen penny stocks with huge floats take months to move up or down 4 cents. The underlying stock was trading around 10 cents. I’ve also seen low float penny stocks closer to $5 run 100% or more in a single day. If you remember KODK from earlier this year, we saw the penny stock jump from around $2.13 to highs of $60 in less than a week.
It also came down just as quickly. At the end of the day, the price of penny stocks is just one aspect to account for in your trading strategy. With this in mind, let’s take a look at a few penny stocks that have started to trend higher this week.
Penny Stocks To Watch: Revive Therapeutics Ltd.
Revive Therapeutics Ltd. (RVVTF Stock Report)(RVV) has chosen to focus on using existing drugs to address COVID and its side effects. While the company has diversified its offerings across a number of biotech indications, the recent focus has been on its coronavirus treatment. The company’s Bucillamine is becoming a standout among coronavirus treatment candidates.
Revive also affirmed that it may unrealized potential for the treatment of influenza with both proven safety and proven mechanism of action similar to that of something known as NAC, or N-acetylcysteine. NAC is important for a variety of health reasons — including replenishing the most powerful antioxidant in your body, glutathione. These amino acids also help with chronic respiratory conditions, organ vitality, fertility and brain health.
Earlier this year, the FDA recommended that Revive proceed directly into a Phase 3 confirmatory clinical trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 in order to “ensure expeditious evaluation of the safety and efficacy of Bucillamine.”
Fast-forward a bit and Revive Therapeutics Phase 3 clinical trial protocol received IRB approval. Michael Frank, CEO of Revive Therapeutics stated that “with the IRB approval of the Phase 3 study protocol for Covid-19, we can recruit U.S. clinical sites efficiently, allowing us to move forward with providing Bucillamine to patients under our IND that was approved by the FDA.” With a Phase 3 coronavirus candidate in toe, will RVVTF stock be on your watch list in September?
Penny Stocks To Watch: iBio Inc.
Continuing with this trend iBio Inc. (IBIO Stock Report) has also been in the spotlight amid excitement stemming from coronavirus. This was one of the penny stocks we discussed over the weekend after some interesting market activity was seen late last week. Earlier this year IBIO stock exploded on coronavirus news in late-February. That ended up sparking a rally that lasted well into the early 3rd quarter. After a few weeks of consolidation, iBio is back on the list of penny stocks to watch.
The company recently announced a worldwide license agreement with Planet Biotechnology Inc. This deal is for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc. In vitro studies demonstrated that its ACE2-Fc blocks the SARS-CoV-2 virus from infecting Vero E6 cells.
However, this week, IBIO stock could be heating up even more after a big update on September 9th. The company announced that it has selected IBIO-201, its LicKM™-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. In March, iBio filed four provisional patent applications with the U.S. Patent and Trademark Office in support of its Covid-19 vaccine platforms.
[Read More] Top Penny Stocks To Watch Today Following Key Updates
“Our decision to evaluate IBIO-200 and IBIO-201 in tandem, and in combination with multiple adjuvants, proved beneficial given the results observed with IBIO-201 in preclinical studies,” said Tom Isett, Chairman & CEO of iBio. “While IBIO-201 produced significantly higher anti-spike neutralizing antibody titers than IBIO-200, we are still encouraged by the potential of IBIO-200.”
Penny Stocks To Watch: Heat Biologics
Sticking with the COVID-19 stock trend, Heat Biologics (HTBX Stock Report) has experienced bullish trading this week. After falling for weeks, HTBX stock saw its first real green day on Tuesday. I say “real” because prior to that, HTBX did see some green days, technically, but they weren’t anything major. Tuesday’s trading session saw a clear, bullish trend, which seems to have continued into the Wednesday premarket session.
The company announced that it will participate in a virutal panel this week. It’s titled “New Approaches to COVID-19: Hidden Breakthroughs.” Heat’s CEO, Jeff Wolf joins other industry executives from companies like AIM ImmunoTech, Avalon GlobloCare Corp., ImmunoPrecise Antibodies Ltd., and Orgenesis Inc.
Heat just won a U.S. patent covering compositions of matter that are part of its gp96 platform in combination with a T cell costimulatory agonist in a single therapy. The gp96 treatment is what the company’s COVID-19 vaccine candidate is based on. In late-August, the company reported that preclinical vaccine results significantly increased the frequency of systemic and tissue-specific CD8+ T-cells by “conferring cellular immunity that is essential against any viral infection, including SARS-CoV-2.”
Penny Stocks To Watch: Ampio Pharmaceuticals
Late last week we started to watch Ampio Pharmaceuticals Inc. (AMPE Stock Report). It’s a biopharmaceutical company working on several drugs and has moved into the COVID treatment niche. The company recently announced that it is moving forward with a new coronavirus therapy. In late June, The FDA completed its review of Ampio’s Investigative New Drug application for its intravenous Ampion treatment. Ampio began a Phase 1 clinical trial to evaluate IV Ampion as a treatment for COVID-19 patients on supplemental oxygen.
Fast-forward to this week and Ampio came out with another big update. The company announced positive results in an early trial for intravenous Ampion treatment for COVID-19 patients. The company said its study met its primary endpoint for the safety and tolerability of IV Ampion treatment. There were also no “remarkable differences” in the incidence, frequency, and severity of adverse events between IV Ampion and standard of care. All patients treated with IV Ampion improved after treatment.
Read More
- 4 Penny Stocks To Watch Ahead Of The Snowflake IPO If You Like Tech
- Are These Beaten Down Penny Stocks A Buy Right Now? 4 To Watch
Furthermore, at hospital discharge, the IV Ampion treatment group had a stronger clinical improvement than the COVID standard of care control group. This is as determined by both the World Health Organization clinical improvement scale and the National Early Warning Score. Considering the share-up in coronavirus vaccine stocks recently, will AMPE find itself on more watch lists this month?
Click here for full disclaimer
